Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 67.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,298 shares of the biopharmaceutical company’s stock after selling 129,025 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in TG Therapeutics were worth $2,287,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Jump Financial LLC raised its holdings in TG Therapeutics by 551.8% in the 2nd quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock valued at $11,518,000 after acquiring an additional 270,922 shares in the last quarter. Marex Group plc bought a new position in shares of TG Therapeutics in the second quarter worth $10,017,000. KLP Kapitalforvaltning AS increased its position in shares of TG Therapeutics by 7.7% in the second quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock worth $1,108,000 after purchasing an additional 2,200 shares during the period. Yorktown Management & Research Co Inc acquired a new position in TG Therapeutics in the second quarter valued at about $383,000. Finally, Norges Bank bought a new stake in TG Therapeutics during the second quarter worth about $3,233,000. 58.58% of the stock is owned by institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the sale, the director directly owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.64% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $30.00 on Friday. The company’s 50 day moving average price is $30.78 and its two-hundred day moving average price is $32.16. The firm has a market capitalization of $4.76 billion, a P/E ratio of 10.79 and a beta of 1.86. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The company had revenue of $161.71 million during the quarter, compared to analysts’ expectations of $152.12 million. During the same period in the prior year, the company earned $0.02 EPS. TG Therapeutics’s revenue was up 92.7% compared to the same quarter last year. On average, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on TGTX shares. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. boosted their price objective on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. HC Wainwright started coverage on TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price for the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $50.75.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.